Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons

• ClinicalTrials.gov Identifier: NCT04401449
• Recruitment Status: Recruiting
• First Posted: May 26, 2020
• Last Update Posted: January 13, 2021
• Sponsor: National Institutes of Health Clinical Center (CC)
• Information provided by (Responsible Party): National Institutes of Health Clinical Center (CC)

Tracking Information

• First Submitted Date: May 22, 2020
• First Posted Date: May 26, 2020
• Last Update Posted Date: January 13, 2021
• Actual Study Start Date: January 8, 2020
• Estimated Primary Completion Date: May 1, 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: May 22, 2020)

Inflammatory responses of cells in lung and circulation [ Time Frame: From onset of illness in hospital through acute phase ( days 1 28 more or less 7), at the time of resolution of infection ( day 28 more or less 7 to 6 weeks, andduring convalescence (6 months to 1 year after the infection) ]

Link inflammatory responses present in blood, urine and bronchoalveolar lavage with imaging of COVID-19 target organs (lungs, heart, brain and kidneys) during the earliest stages of infection and at subsequent time points as the infection and host responses evolve, through recovery.

• Original Primary Outcome Measures: Same as current
• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons
• Official Title: Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons (COVID ARC 19)

Brief Summary

Background:

COVID-19 virus infection differs among people. Some people have no or mild symptoms. For others, COVID-19 is life threatening and causes damage to the body s organs. Researchers want to better understand the virus to learn how to kill it.

Objective:

To understand how the COVID-19 virus causes wide differences in how sick one can become from the infection.

Eligibility:

People ages 18-80 with COVID-19 infection

Design:

Participants will be screened with a review of their medical records.

Participants who enter the study at the beginning of their COVID-19 infection will stay in the hospital until they are healthy enough to go home. Those who enter after they have recovered may need to stay in the hospital 1-2 nights to perform the study tests.

Participants will have MRI and CT scans of the brain, heart, and lungs. They will lie in a machine that takes pictures of the body. For the MRI, soft padding or a coil will be placed around their head and chest. They may receive a dye injected into a vein.

Participants will have an ultrasound of the kidneys and heart.

Participants will provide blood and urine samples. They will provide nasal swabs.

Participants will have a bronchoscopy. A thin tube will be placed through the nose or mouth into the airway. Saltwater will be squirted into the lungs and removed by suction.

Participants may provide a spinal fluid sample. A needle injected into the spinal canal will obtain fluid.

Participants will have lung and heart function tests.

At various points after recovery, participants will repeat many of these tests.

Detailed Description

There is little sequential, methodically collected data on patients with COVID-19 that can be correlated with the severity of disease or the long-term sequelae. Such information is necessary to understand how to most logically intervene with directly acting antiviral agents and immunologic response modifiers. The variability of the clinical course of patients who may be asymptomatic throughout their clinical course to those patients who develop progressive multisystem organ failure represents a challenge to understand the host and viral factors that result in these dramatically different outcomes.

This protocol will enroll patients to the Clinical Center in a longitudinal study using granular clinical, laboratory, and imaging data including extensive pulmonary and cardiac functional assessments, neurologic evaluation, comprehensive immunologic evaluations, and innovative imaging. In patients with COVID-19 infection, linking sequential analysis of blood, urine and bronchoalveolar lavage with simultaneous cardiopulmonary imaging can provide novel insights into mechanisms associated with the initiation, progression and resolution of lung, cardiac and systemic inflammation. These mechanisms are presumed to be essential in the pathogenesis and survival from this infection. This information will help guide diagnostic and therapeutic innovation and assess long-term consequences of this infection.

• Study Type: Observational
• Study Design: Observational Model: Cohort; Time Perspective: Prospective
• Target Follow-Up Duration: Not Provided
• Biospecimen: Not Provided
• Sampling Method: Probability Sample
• Study Population: Subjects 18-80 years old, male or female will be enrolled within 14 - 28 days of documented COVID-19 infection for acute care OR during recovery and convalescent phase of the acute illness (day 28 and beyond) if care has been received at a facility outside of NIH. Subject will be from the MDV medtropolitan area.

Condition

• Acute and Long Term Effects of COVID-19:on Systemic Inflammation
• Acute and Long Term Effects of COVID-19 on Lung Function
• Acute and Long Term Effects of COVID-19 on Mrain Function
• Acute and Long Term Effects of COVID-19 on Cardiac Function
• Acute and Long Term Effects of COVID-19 on Kidney Function

• Intervention: Not Provided

Study Groups/Cohorts

• Acutely illl subjects
  COVID-19 subjects treated at the Clinical Center, followed through recovery and intoconvalescence
• Recovered subjects
  COVID-109 subjects who were treated at other hospitals, followed through recovery and into convalescence

Publications *

• CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346. doi: 10.15585/mmwr.mm6912e2.
• Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020 Jun 1;77(6):683-690. doi: 10.1001/jamaneurol.2020.1127.
• Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, Brown TS, Der Nigoghossian C, Zidar DA, Haythe J, Brodie D, Beckman JA, Kirtane AJ, Stone GW, Krumholz HM, Parikh SA. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol. 2020 May 12;75(18):2352-2371. doi: 10.1016/j.jacc.2020.03.031. Epub 2020 Mar 19. Review.

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: August 6, 2020): 180
• Original Estimated Enrollment (submitted: May 22, 2020): 92
• Estimated Study Completion Date: May 1, 2024
• Estimated Primary Completion Date: May 1, 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

• INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

Subjects within 1-28 days of documented COVID-19 infection for acute care:

• Stated willingness to comply with all study procedures and availability for the duration of the study

• Male or female, aged 18 to 80 years

  • Only a minority of children and adolescents have been described as developing serious illness with COVID-19 infection. As such, this is not an age group at significant risk from complications due to this infection. Adults older than 80 years of age represent a group with the greatest risk of mortality from COVID-19 infection. The presence of significant co-morbidities requiring care that cannot be

provided at the CC would present a disadvantage to them to have their acute care provided for in the CC.

• Documentation of positive SARSCoV-19 test by nucleic acid detection (COVID-19 infection , RT-PCR)
• Ability of subject to understand and the willingness to sign a written informed consent document.

Subjects during recovery phase of the acute illness (day 28 and beyond) if care has been received at a facility outside of NIH:

• Stated willingness to comply with all study procedures and availability for the duration of the study
• Male or female, aged 18 to 80 years

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

• Pregnancy or lactation

• Serious mental illness (e.g. schizophrenia, manic depression) that would limit the ability of the participant to participate willingly into the study.

  --The conduct of the study requires participation in studies that may be unduly stressful (e.g. MRI, bronchoscopy).

• Severe claustrophobia that would prohibit the conduct of imaging by MRI even if sedation is provided.
• Patients requiring mechanical ventilation at an outside hospital prior to transfer. Transporting these patients adds risk to their care.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 80 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Natural History COVID Study (COVID ARC 1; Not Listed; nathx_covid@nih.gov

• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT04401449
• Other Study ID Numbers: 200113; 20-CC-0113
• Has Data Monitoring Committee: Not Provided

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Responsible Party: National Institutes of Health Clinical Center (CC)
• Study Sponsor: National Institutes of Health Clinical Center (CC)
• Collaborators: Not Provided

Investigators

• Principal Investigator: Anthony F Suffredini, M.D.; National Institutes of Health Clinical Center (CC)

• PRS Account: National Institutes of Health Clinical Center (CC)
• Verification Date: December 7, 2020